Organon/$OGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Organon
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Ticker
$OGN
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
10,000
ISIN
US68622V1061
Website
Organon Metrics
BasicAdvanced
$2.6B
3.48
$2.88
0.56
$0.86
0.80%
Price and volume
Market cap
$2.6B
Beta
0.56
52-week high
$23.10
52-week low
$8.01
Average daily volume
4.1M
Dividend rate
$0.86
Financial strength
Current ratio
1.672
Quick ratio
0.77
Long term debt to equity
1,648.708
Total debt to equity
1,914.407
Dividend payout ratio (TTM)
39.73%
Interest coverage (TTM)
2.67%
Profitability
EBITDA (TTM)
1,704
Gross margin (TTM)
57.32%
Net profit margin (TTM)
11.92%
Operating margin (TTM)
21.75%
Effective tax rate (TTM)
-11.61%
Revenue per employee (TTM)
$630,000
Management effectiveness
Return on assets (TTM)
7.03%
Return on equity (TTM)
254.24%
Valuation
Price to earnings (TTM)
3.482
Price to revenue (TTM)
0.41
Price to book
4.77
Price to tangible book (TTM)
-0.47
Price to free cash flow (TTM)
4.404
Free cash flow yield (TTM)
22.70%
Free cash flow per share (TTM)
227.50%
Dividend yield (TTM)
8.58%
Forward dividend yield
0.80%
Growth
Revenue change (TTM)
-0.84%
Earnings per share change (TTM)
-29.44%
3-year revenue growth (CAGR)
-0.37%
3-year earnings per share growth (CAGR)
-17.34%
3-year dividend per share growth (CAGR)
10.06%
What the Analysts think about Organon
Analyst ratings (Buy, Hold, Sell) for Organon stock.
Bulls say / Bears say
Organon's acquisition of Dermavant, including the innovative dermatologic therapy VTAMA® (tapinarof) cream, enhances its dermatology portfolio and positions the company to capture a larger market share in the treatment of chronic inflammatory skin conditions. (stocktitan.net)
The FDA's acceptance of the Biologics License Application for HLX14, a biosimilar candidate of PROLIA/XGEVA (denosumab), indicates potential future revenue streams and strengthens Organon's biosimilars pipeline. (stocktitan.net)
Organon's appointment of Ramona A. Sequeira, a seasoned pharmaceutical executive, to its Board of Directors brings valuable industry experience that could drive strategic growth initiatives. (stocktitan.net)
Organon's stock plummeted 27% following the announcement of a significant dividend cut from $0.28 to $0.02 per share, leading to a shareholder class action lawsuit alleging potential violations of federal securities laws. (businesswire.com)
The company reported a 6.7% year-on-year decline in Q1 2025 revenue to $1.51 billion, indicating potential challenges in maintaining sales growth. (smdailypress.com)
Organon's operating margin decreased to 21.5% in Q1 2025 from 23.2% in the same quarter the previous year, reflecting potential profitability challenges. (dailytimesleader.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Organon Financial Performance
Revenues and expenses
Organon Earnings Performance
Company profitability
Organon News
AllArticlesVideos
Organon & Co. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights – OGN
GlobeNewsWire·5 hours ago
OGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewsWire·5 hours ago
Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
GlobeNewsWire·8 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Organon stock?
Organon (OGN) has a market cap of $2.6B as of July 12, 2025.
What is the P/E ratio for Organon stock?
The price to earnings (P/E) ratio for Organon (OGN) stock is 3.48 as of July 12, 2025.
Does Organon stock pay dividends?
Yes, the Organon (OGN) stock pays dividends to shareholders. As of July 12, 2025, the dividend rate is $0.86 and the yield is 0.8%. Organon has a payout ratio of 39.73% on a trailing twelve-month basis.
When is the next Organon dividend payment date?
The next Organon (OGN) dividend payment date is unconfirmed.
What is the beta indicator for Organon?
Organon (OGN) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.